Phase I dose-escalation study of the safety, tolerability, and pharmacokinetics of aflibercept in combination with S-1 in Japanese patients with advanced solid malignancies

Toshihiko Doi1 · Narikazu Boku2 · Yusuke Onozawa3 · Keishiro Takahashi4 · Osamu Kawaguchi5 · Atsushi Ohtsu1

Received: 28 August 2019 / Accepted: 13 December 2019 / Published online: 6 January 2020 © The Author(s) 2020

Summary
Background Aflibercept, a recombinant fusion protein binding VEGF-A, VEGF-B and placental growth factor, inhibits tumor growth by blocking angiogenesis. The aim of this phase I dose-escalation study was to determine the recommended phase II dose (RP2D) of aflibercept in combination with S-1 in Japanese patients with solid tumors. Patients and methods Sequential cohorts of 3–6 patients with metastatic or unresectable solid tumors, who had failed at least one prior line of standard treatment or who were not suitable for such treatment, were to receive escalating doses of aflibercept every 2 weeks, starting at 2 mg/kg, combined with S-1 at 40 mg/m² twice daily (80 mg/m²/day; 4 weeks on/2 weeks off). Dose-escalation was to be based on the incidence of dose-limiting toxicity (DLT). Blood samples were collected for pharmacokinetic analysis. Results At the first dose level (aflibercept 2 mg/kg plus S-1) 1 of 6 patients experienced a DLT (grade 4 proteinuria). The aflibercept dose was consequently escalated to 4 mg/kg; 1 of 3 patients treated at this dose level had a DLT (grade 2 pleural effusion), and another patient experienced grade 3 reversible posterior leukoencephalopathy syndrome after the DLT assessment period. Additional patients were therefore enrolled into the first dose level to explore safety and tolerability. The study was subsequently terminated prematurely. The maximum tolerated dose was not reached and the RP2D was not determined in Japanese patients. Conclusions The tolerability and safety of aflibercept 2 mg/kg in combination with S-1 was confirmed in Japanese patients with advanced solid tumors.

Keywords Aflibercept · S-1 · Phase I trial · Japanese · VEGF trap

Introduction
The process of angiogenesis plays a crucial role in tumor growth and metastasis [1]. New blood vessels from existing vasculature maintain a source of nutrition and oxygen for the tumor from the host. Although the mechanism of angiogenesis is complex, involving multiple signaling pathways, the proangiogenic cytokine, vascular endothelial growth factor A (VEGF-A), is of key importance [2]. VEGF-A is a homodimeric protein which binds to and activates two high-affinity receptors, VEGFR-1 (also known as FLT-1) and VEGFR-2 (also known as KDR) [3]. Furthermore, VEGF-A acts as a powerful mitogen for endothelial cells and increases vessel permeability very potently. Thus, VEGF-A promotes the formation of new vessels that are required for tissue growth [2, 3].

VEGF-A has been reported to be overexpressed in several types of human cancer and associated with increased tumor vascularity, proliferation, progression, invasion, metastasis, and poor prognosis [4, 5]. Therefore, VEGF-A is a major target for anti-angiogenic therapy. Clinical studies with bevacizumab, an anti-VEGF-A antibody, have shown that targeting this growth factor is effective for the clinical management of metastatic colorectal cancer (mCRC) [6, 7].
advanced non-small cell lung cancer [8], metastatic renal cancer [9, 10], and glioblastoma multiforme [11].

Aflibercept (also known as ziv-aflibercept in the United States; aflibercept beta in Japan) is a soluble, decoy receptor construct which incorporates the second immunoglobulin (Ig)-like domain of VEGFR-1 joined to the third Ig-like domain of VEGFR-2, which are fused to the Fc portion of human IgG1 [12, 13]. This construction allows aflibercept to bind all isoforms of VEGF-A at subpicomolar affinity levels [14]. In addition, aflibercept also binds two more growth factors, placenta growth factor (PlGF) and VEGF-B [15]. Data from patient-derived colorectal cancer xenograft models have shown aflibercept to exhibit greater antitumor activity than bevacizumab [16]. The VELOUR study, a large randomized, placebo-controlled, phase III trial, demonstrated that addition of aflibercept to infusional 5-fluorouracil (5-FU), folinic acid and irinotecan (FOLFIRI) significantly improved overall survival compared with placebo plus FOLFIRI in patients with mCRC previously treated with an oxaliplatin-containing regimen [17]. Aflibercept was administered intravenously in this study, which enrolled predominantly Caucasian patients, at a dose level of 4 mg/kg every 2 weeks. A phase I study has demonstrated that FOLFIRI plus aflibercept at a dose level of 4 mg/kg every 2 weeks has a manageable toxicity profile, pharmacokinetic (PK) parameters consistent with findings in Caucasian patients, and promising efficacy in Japanese patients with mCRC previously treated with at least one chemotherapy regimen [18].

Preclinical assessment of aflibercept with 5-FU in tumor-bearing mice showed that the combination was synergistic and that there was no overlap in host toxicity (Sanofi, data on file). S-1 is an oral fluoropyrimidine formulation including tegafur, a prodrug of 5-FU; gimeracil (5-chloro-2,4-dihydroxypyridine [CDHP]), an inhibitor of 5-FU catabolism; and oteracil, which decreases 5-FU activation in the gut, thereby reducing gastrointestinal toxicity.

The primary objective of this phase I dose-escalation study was to determine the recommended phase II dose (RP2D) of aflibercept that could be safely administered intravenously once every 2 weeks in combination with S-1 in Japanese patients.

Materials and methods

Study population

Patients aged ≥20 years, with a histologically or cytologically confirmed solid malignancy that was recurrent or unresectable, for which S-1 treatment had regulatory approval in Japan, were eligible for inclusion. They must also have had failure of at least one prior line of standard treatment or be unsuitable for standard care, an Eastern Cooperative Oncology Group (ECOG) performance status ≤2; adequate organ function (hemoglobin ≥9.0 g/dL; absolute neutrophil count ≥1.5 × 109/L; platelets ≥100 × 109/L; creatinine ≤1.0 x upper limit of normal (ULN) or creatinine clearance calculated according to the Cockroft-Gault formula ≥60 mL/min if between 1.0 to ≤1.5 x ULN; either proteinuria ≤500 mg/24 h or urine protein:creatinine ratio ≤1; aspartate aminotransferase and alanine aminotransferase ≤2.5 x ULN, total bilirubin ≤1.5 x ULN, and serum albumin ≥3.0 g/dL). All toxic effects of prior anticancer therapy, excluding alopecia, must have resolved to grade ≤1.

Exclusion criteria were: a diagnosis of squamous cell lung cancer; an anticipated need for a major surgical procedure or radiation therapy during the study; history of hypersensitivity to recombinant proteins, or fluoropyrimidines, including S-1 or severe drug allergy; treatment with chemotherapy, hormonal therapy, radiotherapy, surgery, blood products, or any investigational agent within the 28 days (42 days for nitrosourea agents, mitomycin C, or immunotherapy) prior to study enrollment; known dihydroxyrimidine dehydrogenase deficiency; cumulative radiation therapy to ≥25% of the total bone marrow; uncontrolled hypertension defined as blood pressure (BP) >150/100 mmHg on at least two repeat determinations on separate days within 4 weeks prior to enrollment; severe cardiac, cerebral or gastrointestinal or thromboembolic events within 180 days prior to study entry; history of brain metastases, spinal cord compression, or carcinomatous meningitis, or new evidence of brain or leptomeningeal disease on screening computed tomography (CT) or magnetic resonance imaging (MRI) scan; peritoneal metastases clearly detectable by CT or MRI; peritoneal metastases clearly detectable by CT or MRI; malignant ascites requiring drainage; active infection, hepatitis C virus, hepatitis B virus surface antigen positive or on antiviral therapy for human immunodeficiency virus; clinically significant bleeding diathesis or underlying coagulopathy; administration of warfarin; pregnant or breast-feeding; prior treatment with an investigational product (prior treatment with S-1 was permitted, unless inclusion was inappropriate for safety reasons).

Study design

This was a dual-center, open-label, sequential-cohort dose-escalation study of aflibercept administered intravenously every 2 weeks in combination with S-1 in Japanese patients with advanced solid malignancies. The study was designed as a hybrid phase I study starting with single agent therapy proceeding to combination therapy, comprising an aflibercept single-agent 2-week run-in phase followed by a combination phase with S-1. The primary objective of the study was to determine the RP2D of aflibercept in combination with S-1 in Japanese patients. Secondary objectives included assessments of safety, dose-limiting toxicity (DLT), PK, antitumor activity and the immunogenicity of aflibercept.
The protocol was approved by the Institutional Review Boards at both participating centers and the study was conducted in accordance with the ethical principles laid out in the Declaration of Helsinki. All patients provided written informed consent prior to enrollment.

**Drug dose and administration**

The planned starting dose of aflibercept was 2 mg/kg every 2 weeks, based on previous studies in other populations. Two further dose levels were planned: 4 mg/kg every 2 weeks and 6 mg/kg every 2 weeks. Aflibercept was to be administered intravenously over 1 h according to the assigned dose level every 2 weeks. Cycle 1 extended over 8 weeks, with subsequent cycles being 6 weeks. In the first 2 weeks of cycle 1 (single-agent phase), patients initially received a single administration of aflibercept, and then from day 15, patients received aflibercept in combination with oral S-1 at 40 mg/m² twice daily (80 mg/m²/day), administered to day 42, followed by 2 weeks off. In subsequent 6-week cycles, S-1 was administered on days 1 to 28 (4 weeks on/2 weeks off) with aflibercept administered every 2 weeks. From the starting dose level of 2 mg/kg, sequential cohorts of 3–6 patients were to be treated at escalating dose levels of aflibercept, while the dose of S-1 was constant at 40 mg/m² twice daily. The study followed a standard 3 + 3 design and dose escalation was to be based on the occurrence of DLT (≤33% of all evaluable patients at a particular dose level) during the first cycle. Intrapatient dose escalation was not permitted.

The maximum tolerated dose (MTD) was defined as the lowest dose level at which ≥33% of all evaluable patients experienced DLT in cycle 1. If the MTD was reached, then the highest dose level below the MTD would be the RP2D. The RP2D of aflibercept in combination with S-1 was to be therefore the highest aflibercept dose at which 0 of 3 or 1 of 6 (<33%) of all evaluable patients experienced DLT during the first cycle. To further explore the safety and preliminary efficacy profile of the RP2D, the cohort receiving RP2D was to be expanded by up to 10 additional patients. If the MTD was not reached, the highest dose level cohort was to be expanded by 7 additional patients to further explore the safety of the combination; the RP2D would subsequently be determined based on safety and PK data for all patients at that dose level.

**Safety assessments and definition of DLT**

Adverse events were graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 3.0. Treatment-emergent adverse events (TEAEs) were defined as adverse events that were reported by the site investigator during the on-treatment period (from the start of treatment up to 30 days after the last dose of aflibercept). DLT was defined as any of the following events observed during the first treatment cycle: grade 3 or 4 neutropenia complicated by fever (≥38.5 °C) or infection; grade 4 neutropenia persisting for at least 7 days; grade 4 thrombocytopenia, or grade 3 thrombocytopenia complicated by hemorrhage; any grade 3 non-hematological adverse event except fatigue, anorexia, nausea, vomiting, hypotenension (unless these adverse events was subsequently judged to be DLTs by the Study Committee, considering their frequency, duration, or requirement for excessive supportive therapy); any grade 4 non-hematological toxicity; uncontrolled hypertension defined as systolic BP >150 mmHg or diastolic BP >100 mmHg (or >180/90 mmHg if the patient had a history of pre-existing systolic hypertension) despite 4 weeks of medical management; urinary protein excretion of >3.5 g per day that does not recover to <2.0 g per 24 h within 2 weeks; symptomatic thromboembolic events including cerebrovascular accidents, myocardial infarctions, transient ischemic attacks, new onset or worsening of pre-existing angina.

**Efficacy assessment**

Following a baseline evaluation by CT or MRI scans covering the head, chest, abdomen and pelvis, tumor response was assessed using the same method on day 15 and on day 42 of every treatment cycle beyond cycle 1. Tumor assessment was added to confirm a partial or complete response (4–6 weeks after initial documentation of response), whenever disease progression was suspected, and at the end of study treatment. Tumor response was evaluated according to Response Evaluation Criteria in Solid Tumors version 1.0 [19].

**Pharmacokinetics and immunogenicity**

Blood samples (4.5 mL) for the analysis of plasma concentrations of free and VEGF-bound aflibercept were collected: before, at the end of, and 1, 3, 7 (day 1), 23, 29 (day 2), 47 (day 3) and 167 (day 8) hours after the end of the first infusion of aflibercept, and before administration on days 15, 29 and 42 during cycle 1 (predose). After cycle 2, blood samples were collected before each aflibercept infusion, and additionally 30 and 90 days after the last aflibercept administration. Free and VEGF-bound aflibercept levels in plasma were measured by a validated direct enzyme linked immunosorbant assay (ELISA). Concentrations of VEGF-bound aflibercept were expressed as free aflibercept equivalents (adjusted values) for PK analysis. The lower limit of quantification (LLOQ) was 31 ng/mL and 44 ng/mL (adjusted) for free and VEGF-bound aflibercept, respectively.

Blood samples (5 mL) for measuring the plasma concentrations of S-1 related compounds (tegafur, including the active metabolite of tegafur, 5-FU, CDHP and oteracil) were taken before the start of aflibercept infusion on day 42 of cycle...
1, 1 h after the start of the aflibercept infusion, and 2, 4, 8, 24 and 48 h after S-1 administration. The third administration of aflibercept during cycle 1 was administered on day 42 instead of day 43 in order to evaluate the pharmacokinetic interaction with S-1. Tegafur concentration was measured by high performance liquid chromatography and 5-FU, CDHP and oteracil concentrations were measured by gas chromatography-negative ion chemical ionization mass spectrometry (GC-NICI-MS). The LLOQ of tegafur, 5-FU, CDHP and oteracil in plasma was 10 ng/mL, 1 ng/mL, 2 ng/mL and 1 ng/mL, respectively.

PK parameters calculated included: area under the concentration versus time curve extrapolated to infinity (AUC); AUC from time 0 to the real time t last (AUC last); AUC from time 0 to 336 h (AUC 0–336); AUC from time 0 to the end of the dosing period (AUC t–336 h for aflibercept and 12 h for S-1); total body clearance (CL); total body clearance at steady state (CL ss); maximum drug concentration observed (C max); terminal half-life (t 1/2z); first time to reach C max (T max); and apparent volume of distribution at steady state (V ss). PK parameters were calculated using noncompartmental analysis on a validated PK data management system using WinNonlin Professional, Version 5.2.1 (Pharsight).

To screen for the presence of aflibercept antibodies in serum, blood samples (4.0 mL) were collected predose on day 1 of every odd-numbered cycle, upon study withdrawal and 90 days after study treatment discontinuation. Antibody levels were measured using a validated ELISA method, with an LLOQ of 52.7 IU/mL.

Results

Patients

Thirteen Japanese patients (7 female) were enrolled. Baseline characteristics are summarized in Table 1. The median age of the patients was 57 years, and all had an ECOG performance status of 0 or 1. The most common primary tumor sites were rectum (n = 6), colon (n = 4) and stomach (n = 2). The median number of lines of prior chemotherapy was 3 (range 2–5). Twelve patients were evaluable for DLT. One patient was not evaluable for DLT due to poor S-1 compliance. All 13 enrolled patients were evaluable for safety, PK and immunogenicity.

Evaluation of DLT

At the initial 2.0 mg/kg dose level, 1 DLT (grade 2 proteinuria/nephrotic syndrome) was observed in 1 of the first 3 enrolled patients. Consequently, 3 more patients were enrolled at dose level 1. As no further DLTs occurred, the dose was increased to 4.0 mg/kg. Of the first 3 patients treated at this dose level, 1 patient experienced a grade 2 pleural effusion which was deemed to be a DLT by the Study Committee, considering the patient’s overall medical condition (bilateral pleural effusion accompanied by uncontrolled BP, proteinuria, and peripheral edema). In accordance with the protocol, 3 additional patients should therefore have been enrolled at the 4.0 mg/kg dose level. However, after the DLT assessment period, another patient developed grade 3 reversible posterior leukoencephalopathy syndrome (RPLS), which would have been considered a DLT if the event had occurred during the DLT assessment period. The sponsor discussed this with the Efficacy and Safety Evaluation Committee. Since this was the first study to administer aflibercept in Japanese patients, the Efficacy and Safety Evaluation Committee recommended that full consideration should be given to DLT events even those occurring outside the DLT evaluation period. Responding to this recommendation, the sponsor amended the protocol to

| Table 1 | Baseline patient and disease characteristics |
|----------|-----------------------------------------|
| Characteristic | Aflibercept dose level | All patients (N = 13) |
| | 2 mg/kg (N = 10) | 4 mg/kg (N = 3) |
| Sex, n (%) | | |
| Female | 6 (60) | 1 (33) | 7 (54) |
| Male | 4 (40) | 2 (67) | 6 (46) |
| Age, years | | |
| Median | 56.0 | 64.0 | 57.0 |
| Range | 36–73 | 34–74 | 34–74 |
| Weight, kg | | |
| Median | 58.05 | 58.20 | 58.20 |
| ECOG PS, n (%) | | |
| 0 | 7 (70) | 2 (67) | 9 (69) |
| 1 | 3 (30) | 1 (33) | 4 (31) |
| Primary tumor site, n (%) | | |
| Rectum | 5 (50) | 1 (33) | 6 (46) |
| Colon | 3 (30) | 1 (33) | 4 (31) |
| Breast | 1 (10) | 0 | 1 (8) |
| Stomach | 1 (10) | 1 (33) | 2 (15) |
| Prior anticancer therapy, n (%) | | |
| Chemotherapy | 10 (100) | 3 (100) | 13 (100) |
| Fluoropyrimidine based | 10 (100) | 3 (100) | 13 (100) |
| Anti-VEGF antibody | 2 (20) | 2 (67) | 4 (31) |
| Surgery | 8 (80) | 3 (100) | 11 (85) |
| Radiotherapy | 1 (10) | 0 | 1 (8) |
| Number of lines of prior chemotherapy, n (%) | | |
| Median | 3.0 | 3.0 | 3.0 |
| Range | 2–4 | 2–5 | 2–5 |

ECOG PS, Eastern Cooperative Oncology Group performance status

*a* A patient may have received more than one type of prior anticancer therapy
allow reassessment of tolerability and safety at the 2.0 mg/kg dose level before more patients were enrolled at the 4.0 mg/kg dose level. Consequently, 4 additional patients were enrolled at the 2.0 mg/kg dose level. No further DLTs were observed. At this point, the sponsor decided to terminate the study in consideration of the global development status of S-1 treatment for gastric cancer and the progress of this study.

### Safety and tolerability

All 13 treated patients experienced at least 1 TEAE; these were predominantly grade 1 or 2. Incidences for the most common TEAEs are summarized in Table 2. At the 4.0 mg/kg dose level, the most common grade 3/4 TEAE was hypertension, which occurred in 2 patients. One patient in each dose level permanently discontinued study treatment due to a TEAE (grade 4 proteinuria at the 2 mg/kg dose level and grade 2 pleural effusion at the 4 mg/kg dose level). Serious TEAEs were observed in 4 (40%) and 1 (33%) patients at the 2 and 4 mg/kg dose levels, respectively. At the 2.0 mg/kg dose level, serious TEAEs were gingival infection; pneumonia, hyponatremia; cholangitis, hyperbilirubinemia; and proteinuria (1 event each). At the 4.0 mg/kg dose level, serious TEAEs were tumor pain, decreased appetite, reversible posterior leukoencephalopathy syndrome, and nausea (1 event each). There were no serious TEAEs that occurred in more than 1 patient. Grade 4 hypertension was not reported. Grade 3/4 hematological abnormalities of leukocytes, neutrophils, activated partial thromboplastin time, and lymphopenia were observed in 1 patient each (10%) at the 2.0 mg/kg dose level, and no grade 3/4 abnormality was observed at the 4.0 mg/kg dose level. Regarding grade 3/4 biochemical abnormalities, bilirubin (10%), aspartate aminotransferase (20%), alanine aminotransferase (10%), hypertriglyceridemia (10%), hyponatremia (10%), and hyperglycemia (10%) were observed at the 2.0 mg/kg dose level, and bilirubin (33%) was observed at the 4.0 mg/kg dose level. There were no treatment-related deaths.

### Pharmacokinetics and immunogenicity

PK parameters of free and VEGF-bound aflibercept in cycle 1 after a single administration at 2 mg/kg or 4 mg/kg are summarized in Table 3. PK parameters of free and VEGF-bound aflibercept at 2 mg/kg or 4 mg/kg in the presence of S-1 in cycle 1 on day 42 after repeated administrations are summarized in Table 4. In the presence of S-1 (day 42), free aflibercept had a mean half-life of 5.05 and 4.28 days at 2 and 4 mg/kg, respectively, and the median maximum free aflibercept concentration was observed approximately 3 h post-dosing (2 h after the end of the infusion). In the absence of S-1 (day 1), free aflibercept had a mean half-life of 3.77 and 3.86 days at doses of 2 and 4 mg/kg, respectively, and the median maximum free aflibercept concentration was observed approximately 2 h post-dose (1 h after the end of the first infusion). At the dose level of 2 mg/kg, free aflibercept was eliminated with a mean clearance of 0.759 L/day. In the presence of S-1, the mean clearance at steady state was similar, at 0.649 L/day. At the dose level of 4 mg/kg, free aflibercept was eliminated with similar clearances in the presence and absence of S-1. The volume of distribution at steady state was approximately 4 L across aflibercept dose levels regardless of the presence or absence of S-1. Mean free and VEGF-bound plasma concentrations on day 1 of cycle 1 for each dose level cohort are illustrated in Fig. 1. Mean plasma concentration versus time profiles of free, adjusted-bound and total aflibercept on day 42 in cycle 1 after multiple dosing in the presence of S-1 are summarized in Table 5.

### Antitumor activity

Eight of 13 patients (62%) had a best overall response of stable disease (SD), including 6 of 10 (60%) at the 2 mg/kg dose level and 2 of 3 (67%) at the 4 mg/kg level. The primary tumor sites for these 8 patients were rectum (n = 6), colon (n =

---

**Table 2** Incidence of the most common treatment emergent adverse events

| Preferred term, n (%) | Aflibercept dose level |
|-----------------------|------------------------|
|                       | 2 mg/kg (N = 10) | 4 mg/kg (N = 3) |
|                       | All grades | Grade 3/4 | All grades | Grade 3/4 |
| Decreased appetite    | 10 (100) | 1 (10) | 2 (67) | 1 (33) |
| Hypertension          | 7 (70) | 4 (40) | 3 (100) | 2 (67) |
| Diarrhea              | 8 (80) | 0 | 1 (33) | 0 |
| Fatigue               | 7 (70) | 2 (20) | 1 (33) | 1 (33) |
| Nausea                | 7 (70) | 0 | 1 (33) | 0 |
| Constipation          | 6 (60) | 0 | 1 (33) | 0 |
| Stomatitis            | 6 (60) | 0 | 0 | 0 |
| Weight decreased      | 5 (50) | 0 | 1 (33) | 0 |
| Epistaxis             | 5 (50) | 0 | 1 (33) | 0 |
| Proteinuria           | 4 (40) | 1 (10) | 2 (67) | 1 (33) |

*a* Reported in ≥6 patients overall at any grade  
*b* One patient can have more than 1 adverse event  
*c* Adverse events are reported according to the Medical Dictionary for Regulatory Activities version 13.1 and graded using National Cancer Institute Common Toxicity Criteria version 3.0
Table 3  Plasma pharmacokinetic parameters of free and VEGF-bound aflibercept in cycle 1 following single administration at 2 mg/kg or 4 mg/kg

| Aflibercept dose level | Free aflibercept | VEGF-bound aflibercept |
|------------------------|------------------|------------------------|
|                        | 2 mg/kg          | 4 mg/kg                | 2 mg/kg          | 4 mg/kg                  |
| Number of patients     | 10               | 3                      | 10               | 3                        |
| C<sub>max</sub>, μg/mL | 52.5 ± 24.6 (48.0 [46.8] | 70.2 ± 5.94 (70.0 [8.5] | 1.60 ± 0.717 (1.48 [44.7] | 1.50 ± 0.298 (1.48 [19.9] |
| Tmax<sup>a</sup>, days | 0.08             | 0.08                   | 13.97            | 13.98                    |
|                        | (0.04–0.17)      | (0.04–0.08)            | (13.79–14.02)    | (7.00–16.10)             |
| AUC<sub>last</sub>, µg·day/mL | 173 ± 56.2 (166 [32.4]) | 247 ± 51.7 (243 [21.0]) | 13.4 ± 5.44 (12.5 [40.6]) | 13.8 ± 1.16 (13.7 [8.5]) |
| AUC<sub>0–336</sub>, µg·day/mL | 153 ± 32.2 (150 [21.0]) | 243 ± 46.6 (240 [19.2]) | 12.3 ± 6.71 (11.4 [54.4]) | NC ± NC |
| AUC, µg·day/mL         | 166 ± 35.0 (163 [21.1]) | 269 ± 67.7 (263 [25.2]) | NC ± NC         | NC ± NC |
|                        | (3.77 ± 0.858 (3.68 [22.7]) | 3.86 ± 1.47 (3.63 [38.1]) | NC ± NC         | NC ± NC |
| t<sub>1/2c</sub>, day   | 0.759 ± 0.253 (0.730 [33.3]) | 0.917 ± 0.196 (0.903 [21.3]) | NA               | NA |
| V<sub>ss</sub>, L       | 3.53 ± 0.835 (3.43 [23.7]) | 4.57 ± 1.13 (4.48 [24.7]) | NA               | NA |
| CV%, coefficient of variation percentage; NA, not applicable; NC, not calculated; SD, standard deviation; VEGF, vascular endothelial growth factor. PK parameters reported are: AUC, area under the concentration versus time curve extrapolated to infinity; AUC<sub>0–336</sub>, AUC from time 0 to 336 h; AUC<sub>last</sub>, AUC from time 0 to the real time t<sub>last</sub>; CL, total body clearance; C<sub>max</sub>, maximum drug concentration observed; t<sub>1/2c</sub>, terminal half-life; T<sub>max</sub>, first time to reach C<sub>max</sub>; V<sub>ss</sub>, apparent volume of distribution at steady state.

1) and stomach (n = 1). There were no patients with a complete response (CR) or partial response (PR). The median number of cycles with aflibercept administration per patient was 3.0 (range, 1 to 11) at the 2.0 mg/kg dose level and 1.0 (range, 1 to 2) at the 4.0 mg/kg dose level, with an aflibercept median relative dose intensity (RDI) of 0.903 (range, 0.71 to 1.01) at the 2.0 mg/kg dose level and 0.748 (range, 0.25 to 0.79) at the 4.0 mg/kg dose level. Median exposure to S-1 at aflibercept 2.0 mg/kg and 4.0 mg/kg dose levels were 3.0 (range, 1 to 11) and 1.5 (range, 1 to 2) cycles per patient with a median RDI of 0.771 (range, 0.60 to 0.95) and 0.763 (range, 0.73 to 0.80), respectively.

Discussion

The objective of the current study was to define a dose of aflibercept that could be safely administered with S-1 in Japanese patients with advanced solid malignancies for further investigation. The initial plan was that for sequential cohorts of 3–6 patients, the dose level of aflibercept would be escalated from a starting level of 2 mg/kg, while the dose level of S-1 was held constant at 40 mg/m² twice daily. However, because one of the first 3 patients treated at the second dose level of 4 mg/kg developed a DLT and another patient developed RPLS outside the DLT assessment period, we decided to reassess tolerability and safety at the 2.0 mg/kg dose level before proceeding to the 4.0 mg/kg dose level. Subsequently, this study was terminated by the sponsor in consideration of global development status of S-1 treatment for gastric cancer and the progress of this study. The MTD was therefore not reached in this study and a RP2D for aflibercept in combination S-1 in Japanese patients was not defined. However, based on the available data from patients enrolled at the initial dose level, we concluded that aflibercept 2 mg/kg given every 2 weeks in combination with S-1 was tolerable in Japanese patients.

All 13 patients who were assessed for safety experienced at least 1 TEAE. Most of these TEAEs were manageable and predominantly of low grade except for grade 3 hypertension observed in 6 (46%) of all 13 patients. Hypertension and proteinuria (seen at grade 3/4 in 2 [15%] of 13 patients) are commonly associated with anti-VEGF agents [20]. There
were no treatment-related deaths. Serious TEAEs were observed in 4 (40%) and 1 (33%) patients at the 2 and 4 mg/kg dose levels, respectively.

A positive value in the anti-drug antibody (ADA) assay was detected in 3 patients (2 patients at the 2 mg/kg dose level and 1 patient at the 4 mg/kg dose level); these 3 patients also had a

---

**Table 4** Plasma pharmacokinetic parameters of free and VEGF-bound aflibercept on day 42 following repeated administrations at 2 mg/kg or 4 mg/kg in the presence of S-1

| Dose level (Mean ± SD (Geometric mean [CV%])) | Free aflibercept | VEGF-bound aflibercept |
|---------------------------------------------|-----------------|------------------------|
| 2 mg/kg | 4 mg/kg | 2 mg/kg | 4 mg/kg |
| Number of patients | 8 | 1 | 8 | 1 |
| C<sub>max</sub>, μg/mL | 49.6 ± 18.7 (47.0 [37.7]) | 77.5 | 3.72 ± 1.36 (3.49 [36.6]) | 2.91 |
| T<sub>max</sub>, days | 0.13 | 0.13 | 1.04 | 9 |
| AUC<sub>last</sub>, μg·day/mL | 242 ± 134 (0.13–0.37) | 250 | 40.6 ± 12.1 (0.37–8.93) | 44 |
| AUC<sub>τ</sub>, μg·day/mL | 232 ± 125 (218) [55.3] | 242 | 39.3 ± 12.1 (39.1) [29.7] | 37.9 |
| t<sub>1/2z</sub>, day | 5.05 ± 1.66 (4.78) [32.9] | 4.28 | NC ± NC (37.9) [30.9]<sup>a</sup> | NC |
| CL<sub>ss</sub>, L/day | 0.649 ± 0.397 (0.579) [61.2] | 0.813 | NA [NC] | NA |
| V<sub>ss</sub>, L | 3.83 ± 0.987 (3.71) [25.7] | 4.19 | NA | NA |

**CV%**; coefficient of variation percentage; NA, not applicable; NC, not calculated; SD, standard deviation; VEGF, vascular endothelial growth factor. PK parameters reported are: AUC<sub>last</sub> area under the concentration versus time curve (AUC) from time 0 to the real time t<sub>last</sub>; AUC<sub>τ</sub>, AUC from time 0 to the end of the dosing period; CL<sub>ss</sub>, total body clearance at steady state; C<sub>max</sub>, maximum drug concentration observed; t<sub>1/2z</sub>, terminal half-life; T<sub>max</sub>, first time to reach C<sub>max</sub>; V<sub>ss</sub>, apparent volume of distribution at steady state

<sup>a</sup>N = 1, individual values listed
<sup>b</sup>Median (range)
<sup>c</sup>N = 5 (three patients were not evaluable)
<sup>d</sup>N = 0 (none of the patients were evaluable)

---

**Fig. 1** Mean plasma concentration versus time profiles of free, adjusted-bound and total aflibercept on day 1 of cycle 1 following a single administration (semi-log scale)

**Fig. 2** Mean plasma concentration versus time profiles of free and adjusted-bound aflibercept on day 42 of cycle 1 following multiple dosing in the presence of S-1 (semi-log scale)
positive value for ADA at baseline. Although the reasons why patients were positive for ADA before aflibercept was administered are not obvious, this should be investigated before the use of aflibercept in Japanese patients is considered. However, our data suggest that aflibercept might not be highly immunogenic in Japanese patients because ADA did not appear after the administration of aflibercept. No major allergic reactions, such as anaphylactic shock, bronchospasm, generalized urticaria, or infusion related reactions were observed in this study.

Plasma concentrations of free aflibercept and its associated PK parameters were unaffected by repeated dosing of aflibercept in the presence of S-1 at the 2 mg/kg dose level. PK parameters were comparable with those previously reported in a Western population with advanced solid tumors or non-Hodgkin’s lymphomas receiving treatment with aflibercept [21]. The limited data at an aflibercept dose of 4 mg/kg, followed the same trends as those for 2 mg/kg, however, obtained data was insufficient to draw firm conclusions on dose response.

In terms of efficacy, 6 patients at the 2 mg/kg dose level and 2 patients at the 4 mg/kg dose level had SD as a best overall response. There were no CRs or PRs at either dose level in this heavily pretreated population. The limited efficacy observed in this study may be attributed to the low aflibercept dose administered to most patients.

In conclusion, though the MTD was not reached for aflibercept in combination with S-1 in Japanese patients since the study was terminated prematurely, the tolerability and safety of aflibercept at the 2 mg/kg dose level in combination with S-1 was shown, based on DLT incidence and the overall safety profile.

Acknowledgments The authors thank all patients who participated in this study, the Efficacy and Safety Evaluation Committee members: Drs. Hirohyuki Uetake, Yoshihiko Tomita, Ichiei Narita, and medical advisors: Drs. Ichinosuke Hyodo, Hiromichi Suzuki, and Kunihiro Yamagata. Jim Heighway PhD of Cancer Communications and Consultancy Ltd. (Knutsford, UK) provided medical writing services, which were funded by Sanofi.

Author’s contributions Concept or design: KT and OK; data acquisition: TD, NB, YO, and AO; data analysis or interpretation: all authors; drafting the manuscript: TD, KT, and OK; critical revision of the manuscript, final approval of the manuscript, accountability for accuracy and integrity: all authors.

Funding information Financial support for this study was provided by Sanofi K.K.

Compliance with ethical standards

Conflict of interest TD received research funding from Eli Lilly, Kyowa Hakko Kirin, MSD, Daiichi Sankyo, Sumitomo Dainippon, Taiho, Novartis, Merck Serono, Janssen, Boehringer Ingelheim, Pfizer, Chugai

Table 5 Mean pharmacokinetic parameters of S-1 analytes on day 42 following repeated twice daily oral administration of S-1 for two weeks

| S-1 analyte | 5-FU | CDHP | Tegafur | Oteracil |
|-------------|------|------|---------|---------|
| Aflibercept dose level | Mean ± SD | Mean ± SD | Mean ± SD | Mean ± SD |
| 2 mg/kg | 4 mg/kg | 2 mg/kg | 4 mg/kg | 2 mg/kg | 4 mg/kg | 2 mg/kg | 4 mg/kg |
| Number of patients | 7 | 1 | 7 | 1 | 7 | 1 | 7 | 1 |
| Cmax, ng/mL | 130 ± 35.0 | 104 | 367 ± 138 | 266 | 4730 ± 1840 | 4670 | 53.5 ± 38.7 | 29.5 |
| Tmax, h | 2.00 | 3.95 | 1.05 | 1.97 | 1.05 | 1.97 | 1.97 | 3.95 |
| AUCt, ng·h/mL | 912 ± 174 | 654 | 1650 ± 540 | 1320 | 41,600 ± 19,500 | 47,100 | 306 ± 269 | 226 |
| AUClast, ng·h/mL | 788 ± 370 | 817 | 1820 ± 825 | 1730 | 91,400 ± 52,600 | 113,000 | 378 ± 390 | 466 |
| t1/2z, h | 3.66 ± 0.0225 | 3.87 | 3.63 ± 1.13 | 9.2 | 15.7 ± 4.26 | 19.6 | 5.72 ± 3.48 | 19.6 |

CDHP, gimeracil; 5-FU, 5-fluorouracil; SD, standard deviation. PK parameters reported are: AUClast, area under the concentration versus time curve (AUC) from time 0 to the real time t last; AUCt, AUC from time 0 to the end of the dosing period; Cmax, maximum drug concentration observed; t1/2z, terminal half-life; Tmax, first time to reach Cmax.

a n = 1, individual values listed
b Median (range)
c n = 3, 4 patients were not included in the calculation of summary statistics
d n = 2, 5 patients were not included in the calculation of summary statistics
e n = 6, 1 patient was not included in the calculation of summary statistics
f n = 4, 3 patients were not included in the calculation of summary statistics
g n = 6, 1 patient was not included in the calculation of summary statistics
h n = 4, 3 patients were not included in the calculation of summary statistics
Profile of 1 patient was excluded for 5-FU, CDHP, tegafur and oteracil.
Ethical approval  The study protocol was approved by the Institutional Review Boards at both participating centers. The study was conducted in accordance with the principles laid down by the 18th World Medical Assembly (Helsinki, 1964) and all applicable amendments laid down by the World Medical Assemblies, and the ICH guidelines for Good Clinical Practice.

Informed consent  All patients provided written informed consent prior to enrollment.

Open Access  This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

1. Naumov GN, Akslen LA, Folkman J (2006) Role of angiogenesis in human tumor dormancy: animal models of the angiogenic switch. Cell Cycle 5(16):1779–1787
2. Robinson CJ, Stringer SE (2001) The splice variants of vascular endothelial growth factor (VEGF) and their receptors. J Cell Sci 114(Pt 5):853–865
3. Hicklin DJ, Ellis LM (2005) Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 23(5):1011–1027
4. Takahashi Y, Kitadai Y, Bucana CD, Cleary KR, Ellis LM (1995) Expression of vascular endothelial growth factor and its receptor, KDR, correlates with vascular maturity, and proliferation of human colon cancer. Cancer Res 55(18):3964–3968
5. Takebayashi Y, Akiyama S, Yamada K, Akiba S, Aikou T (1996) Angiogenesis as an unfavorable prognostic factor in human colorectal carcinoma. Cancer 78(2):226–231
6. Gianontio BJ, Catalano PJ, Meropol NJ, O'Dwyer PJ, Mitchell EP, Alberts SR, Schwartz MA, Benson AB 3rd (2007) Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFIRI) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E2200. J Clin Oncol 25(12):1539–1544
7. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffling S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R, Kabbinavar F (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350(23):2335–2342
8. Sandler A, Gray R, Perry MC, Brahmer JH, Dowlati A, Lilienbaum R, Johnson DH (2006) Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 355(24):2542–2550
9. Escudier B, Pluzanska A, Koralewski P, Ravaud A, Bracarda S, Szczylik C, Chevreau C, Filipek M, Melichar B, Bajetta E, Gobburuva V, Bay JO, Bodrogi I, Jagiello-Gruszfeld A, Moore N; AVOREN Trial investigators (2007) Bevacizumab plus interferon-alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 370(9605):2103–2111
10. Rini BI, Halabi S, Rosenberg JE, Stadler WM, Vaena DA, Archer L, Atkins JN, Picus J, Czaykowski P, Dutcher J, Small EJ (2010) Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206. J Clin Oncol 28(13):2137–2143
11. Gil-Gil MJ, Mesia C, Rey M, Bruna J (2013) Bevacizumab for the treatment of glioblastoma. Clin Med Insights Oncol 7:123–135
12. Ciomber KK, Berlin J, Chan E (2013) Affiberecept. Clin Cancer Res 19(8):1920–1925
13. Holash J, Davis S, Papadopoulos N, Croll SD, Ho L, Russell M, Boland P, Leidich R, Hylton D, Burova E, Ioffe E, Huang T, Radziejewski C, Bailey K, Fandl JP, Daly T, Wiegand SJ, Yancopoulos GD, Rudge JS (2002) VEGF-trap: a VEGF blocker with potent antitumor effects. Proc Natl Acad Sci U S A 99(17):11393–11398
14. Papadopoulos N, Martin J, Ruan Q, Rafique A, Rosconi MP, Shi E, Pyles EA, Yancopoulos GD, Stahl N, Wiegand SJ (2012) Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF trap, ranibizumab and bevacizumab. Angiogenesis 15(2):171–185
15. Carmeliet P, Moons L, Luttun A, Vincenti V, Comperolle V, De Mol M, Wu Y, Bono F, Devy L, Beck H, Scholz D, Acker T, DiPalma T, Dewerchin M, Noel A, Stalmans I, Barra A, Blacher S, VandenDriessche T, Ponten A, Eriksson U, Plate KH, Foidart JM, Schaper W, Charnock-Jones DS, Hicklin DJ, Herbert JM, Collen D, Persico MG (2001) Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions. Nat Med 7(5):575–583
16. Chiron M, Bagley RG, Pollard J, Mankoo PK, Henry C, Vincent L, Geslin C, Baltes N, Bergstrom DA (2014) Differential antitumor activity of affiberecept and bevacizumab in patient-derived xenograft models of colorectal cancer. Mol Cancer Ther 13(6):1636–1644
17. Van Cutsem E, Tabernero J, Lakomy R, Preuvene H, Prasadova J, Macarulla T, Ruff P, van Hazel GA, Moiseyenko V, Ferry J, Mackintosh J, Bajetta E, Szczylik C, Chevreau C, Filipek M, Melichar B, Ferran M (2008) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. J Clin Oncol 30(28):3499–3506
18. Yoshino T, Yamaizaki K, Yamaguchi K, Doi T, Boku N, Machida N, Onozawa Y, Asayama M, Fujino T, Ohtsu A (2013) A phase I study of intravenous aflibercept with FOLFIRI in Japanese patients with previously treated metastatic colorectal cancer. Investig New Drugs 31(4):910–917
19. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States. Natl Cancer Inst Can J Natl Cancer Inst 92(3):205–216
20. Hayman SR, Leung N, Grande JP, Garovic VD (2012) VEGF inhibition, hypertension, and renal toxicity. Curr Oncol Rep 14(4):285–294
21. Lockhart AC, Rothenberg ML, Dupont J, Cooper W, Chevalier P, Sternas L, Buzenet G, Koehler E, Sosman JA, Schwartz LH, Gultekin DH, Koutcher JA, Donnelly EF, Andal R, Dancy I, Spriggs DR, Tew WP (2010) Phase I study of intravenous vascular endothelial growth factor trap, aflibercept, in patients with advanced solid tumors. J Clin Oncol 28(2):207–214

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.